

Hello Anaka

These are mostly consistent with my recollection of the meeting.

Regarding item 2.2 (1) on page 3, I had raised the question about potential impact of statins dispensed as a private prescription. Lloyd had indicated that this relates to pharmacists dispensing under co-pay scripts as private, but I would like to highlight that it may also relate to prescribers writing private prescriptions, either because the patient is not eligible for Medicare subsidisation or does not meet the eligibility indications for the use of the statin. Lloyd had indicated that the significance of this is likely to be negligible. I have also checked with our Health Economics area and have been advised that while we have no specific information about the private volumes dispensed on a product basis, the total volume of private prescriptions is about 10.3% that of the PBS volume. While this is a significant amount, how much this correlates to potential private use of statins cannot be confirmed.

This information may or may not be of any relevance.

Appreciate being able to attend the meeting.

Regards

**Chris Flood** B.Pharm MPS MACP  
*Senior Pharmacist & National Manager PBS Operations & Strategy  
Pharmacy Viability Group*

**The Pharmacy Guild of Australia  
National Secretariat**

Level 2, 15 National Circuit, Barton, ACT 2600 Australia

PO Box 310, Fyshwick, ACT 2609 Australia

Telephone: 02 6270 1832 · Facsimile: 02 6270 1800

E-mail: [chris.flood@guild.org.au](mailto:chris.flood@guild.org.au) · Internet: [www.guild.org.au](http://www.guild.org.au)

Follow the Guild @ [twitter.com/pharmguildaus](https://twitter.com/pharmguildaus) or [facebook.com/pharmacyguildofaustralia](https://facebook.com/pharmacyguildofaustralia)

**Best Practice Certification ISO9001**